Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast - PubMed (original) (raw)
. 2008 Apr 1;14(7):1956-65.
doi: 10.1158/1078-0432.CCR-07-1465.
Carlo Lucchesi, Nadège Gruel, Virginie Raynal, Gaëlle Pierron, Rémi Goudefroye, Fabien Reyal, François Radvanyi, Rémy Salmon, Jean-Paul Thiery, Xavier Sastre-Garau, Brigitte Sigal-Zafrani, Alain Fourquet, Olivier Delattre; breast cancer study group of the Institut Curie
Collaborators, Affiliations
- PMID: 18381933
- DOI: 10.1158/1078-0432.CCR-07-1465
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast
Anne Vincent-Salomon et al. Clin Cancer Res. 2008.
Abstract
Purpose: To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS).
Experimental design: We did a combined phenotypic and genomic analysis of a series of 57 DCIS integrated with gene expression profile analysis for 26 of the 57 cases.
Results: Thirty-two DCIS exhibited a luminal phenotype; 21 were ERBB2 positive, and 4 were ERBB2/estrogen receptor (ER) negative with 1 harboring a bona fide basal-like phenotype. Based on a CGH analysis, genomic types were identified in this series of DCIS with the 1q gain/16q loss combination observed in 3 luminal DCIS, the mixed amplifier pattern including all ERBB2, 12 luminal and 2 ERBB2(-)/ER(-) DCIS, and the complex copy number alteration profile encompassing 14 luminal and 1 ERBB2(-)/ER(-) DCIS. Eight cases (8 of 57; 14%) presented a TP53 mutation, all being amplifiers. Unsupervised analysis of gene expression profiles of 26 of the 57 DCIS showed that luminal and ERBB2-amplified, ER-negative cases clustered separately. We further investigated the effect of high and low copy number changes on gene expression. Strikingly, amplicons but also low copy number changes especially on 1q, 8q, and 16q in DCIS regulated the expression of a subset of genes in a very similar way to that recently described in invasive ductal carcinomas.
Conclusions: These combined approaches show that the molecular heterogeneity of breast ductal carcinomas exists already in in situ lesions and further indicate that DCIS and invasive ductal carcinomas share genomic alterations with a similar effect on gene expression profile.
Similar articles
- Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM. Castro NP, et al. Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928525 Free PMC article. - Patterns of chromosomal alterations in breast ductal carcinoma in situ.
Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM. Hwang ES, et al. Clin Cancer Res. 2004 Aug 1;10(15):5160-7. doi: 10.1158/1078-0432.CCR-04-0165. Clin Cancer Res. 2004. PMID: 15297420 - An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
Melchor L, Benítez J. Melchor L, et al. Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1. Carcinogenesis. 2008. PMID: 18596026 Review. - The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
Fadare O, Tavassoli FA. Fadare O, et al. Adv Anat Pathol. 2007 Sep;14(5):358-73. doi: 10.1097/PAP.0b013e31814b26fe. Adv Anat Pathol. 2007. PMID: 17717437 Review.
Cited by
- Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package.
Pirrotta S, Masatti L, Bortolato A, Corrà A, Pedrini F, Aere M, Esposito G, Martini P, Risso D, Romualdi C, Calura E. Pirrotta S, et al. NAR Genom Bioinform. 2024 Oct 3;6(4):lqae138. doi: 10.1093/nargab/lqae138. eCollection 2024 Sep. NAR Genom Bioinform. 2024. PMID: 39363890 Free PMC article. - Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival.
Xu C, Liu Y, Wang P, Fan W, Rue TC, Upton MP, Houck JR, Lohavanichbutr P, Doody DR, Futran ND, Zhao LP, Schwartz SM, Chen C, Méndez E. Xu C, et al. Mol Cancer. 2010 Jun 11;9:143. doi: 10.1186/1476-4598-9-143. Mol Cancer. 2010. PMID: 20537188 Free PMC article. - Molecular profiling of patient-derived breast cancer xenografts.
Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Reyal F, et al. Breast Cancer Res. 2012 Jan 16;14(1):R11. doi: 10.1186/bcr3095. Breast Cancer Res. 2012. PMID: 22247967 Free PMC article. - RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.
Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR. Kaur H, et al. PLoS One. 2012;7(12):e50249. doi: 10.1371/journal.pone.0050249. Epub 2012 Dec 6. PLoS One. 2012. PMID: 23236365 Free PMC article. - Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression.
Xu H, Lien T, Bergholtz H, Fleischer T, Djerroudi L, Vincent-Salomon A, Sørlie T, Aittokallio T. Xu H, et al. Front Genet. 2021 Jun 3;12:670749. doi: 10.3389/fgene.2021.670749. eCollection 2021. Front Genet. 2021. PMID: 34149812 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous